Literature DB >> 32149999

Role of Salivary Biomarkers in Predicting Significant Traumatic Brain Injury: An Exploratory Study.

Claudia Yeung1, Rahul Bhatia2, Bikash Bhattarai3, Madhumita Sinha2.   

Abstract

OBJECTIVES: The highest rates of traumatic brain injury (TBI)-related morbidity and mortality occur in young children and adolescents. The objective of this study was to describe the levels of 3 biomarkers (S100B, glial fibrillary acidic protein, neuron-specific enolase) in saliva of children with TBI requiring inpatient admission at a pediatric trauma center and compare these levels in children without TBI.
METHODS: A convenience sample of 24 children aged 0 to 18 years, presenting with acute isolated TBI, was enrolled prospectively. The non-TBI comparison groups consisted of patients with medical complaints and musculoskeletal injuries only. Salivary specimens were collected, and biomarkers were measured using quantitative enzyme-linked immunosorbent assay method. Demographic, clinical data, and brain imaging findings were obtained.
RESULTS: Seventy-four children were enrolled. Twenty-four had TBI (mean age, 5.07 years; SD, 4.8 years); 14 subjects (58.3%) with TBI were found to have significant traumatic brain injury (SBI) on computed tomography scan. S100B levels were significantly higher in TBI group compared with those with musculoskeletal injury only (median, 113.2 pg/mL vs 18 pg/mL; P = 0.021). Area under the receiver operating characteristic curve for S100B in predicting SBI was 0.675; the optimum threshold for S100B to achieve the optimum sensitivity and specificity of SBI was at 86.9 pg/mL for SBI versus no injury group.
CONCLUSIONS: S100B levels in saliva were higher in children with TBI and may be predictive of SBI identified by presence of computed tomography abnormalities. Larger studies are needed to replicate our findings in using a noninvasive diagnostic measure for children with TBI and SBI.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32149999     DOI: 10.1097/PEC.0000000000002050

Source DB:  PubMed          Journal:  Pediatr Emerg Care        ISSN: 0749-5161            Impact factor:   1.454


  5 in total

Review 1.  Pediatric Traumatic Brain Injury: An Update on Preclinical Models, Clinical Biomarkers, and the Implications of Cerebrovascular Dysfunction.

Authors:  Divine C Nwafor; Allison L Brichacek; Chase H Foster; Brandon P Lucke-Wold; Ahsan Ali; Mark A Colantonio; Candice M Brown; Rabia Qaiser
Journal:  J Cent Nerv Syst Dis       Date:  2022-05-22

2.  Is Salivary S100B a Biomarker of Traumatic Brain Injury? A Pilot Study.

Authors:  Damir Janigro; Keisuke Kawata; Erika Silverman; Nicola Marchi; Ramon Diaz-Arrastia
Journal:  Front Neurol       Date:  2020-06-12       Impact factor: 4.003

3.  Salivary S100 calcium-binding protein beta (S100B) and neurofilament light (NfL) after acute exposure to repeated head impacts in collegiate water polo players.

Authors:  Derek C Monroe; Elizabeth A Thomas; Nicholas J Cecchi; Douglas A Granger; James W Hicks; Steven L Small
Journal:  Sci Rep       Date:  2022-03-02       Impact factor: 4.379

4.  GFAP and S100B: What You Always Wanted to Know and Never Dared to Ask.

Authors:  Damir Janigro; Stefania Mondello; Jussi P Posti; Johan Unden
Journal:  Front Neurol       Date:  2022-03-21       Impact factor: 4.003

5.  Peripheral Blood and Salivary Biomarkers of Blood-Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts.

Authors:  Damir Janigro; Damian M Bailey; Sylvain Lehmann; Jerome Badaut; Robin O'Flynn; Christophe Hirtz; Nicola Marchi
Journal:  Front Neurol       Date:  2021-02-04       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.